Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226395 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain
A Phase 3 study of Acute Pain, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT00226395: Completed Phase 3 study of Acute Pain, sponsored by Endo Pharmaceuticals.
NCT00226395 is a Phase 3 study of Acute Pain that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 320 participants, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226395, a Phase 3 study of Acute Pain, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.
Conditions Studied
Interventions
- DRUG Oxymorphone immediate release
Study Locations (20)
Alabama
- Brookwood Medical Center - Birmingham
- The Medical Center, Dept. Clinical research - Birmingham
- Montgomery Women's Health Associates - Montgomery
Arizona
- Arrowhead Community Hospital - Phoenix
- John C Lincoln Hospital - Phoenix
- Paradise Valley Hospital - Phoenix
California
- Glendale Adventist Medical Center - Glendale
- Saddleback Memorial Medical Center - Laguna Hills
- Huntington Memorial Hospital - Pasadena
North Carolina
- Duke University Medical Center - Durham
- Forsyth Medical Center - Winston-Salem
- Medical Park Hospital - Winston-Salem
Florida
- Palm West Hospital - Palm Springs
- Sacred Heart Hospital - Pensacola
Pennsylvania
- Univ. Pittsburgh Hospital - Pittsburgh
- Univ. Pittsburgh Medical center - Pittsburgh
Texas
- Memorial Hermann Memorial City Hospital - Houston
- The Methodist Hospital - Houston
Utah
- Cottonwood Hospital - Salt Lake City
- LDS Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
What the finished NCT00226395 record still lists
NCT00226395 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 1 intervention - of which Oxymorphone immediate release is the first listed.
NCT00226395 names 20 study sites across 8 states, led by Alabama, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00226395 about?
NCT00226395 is a clinical study titled "Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain". The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.
What is the current status of trial NCT00226395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2004-09. Estimated completion is 2005-08.
What conditions does trial NCT00226395 study?
This clinical trial studies the following conditions: Acute Pain.
What interventions are being tested in trial NCT00226395?
The interventions under investigation include: Oxymorphone immediate release (DRUG).
Who is sponsoring clinical trial NCT00226395?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00226395 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00226395's enrollment target sits among peer trials
320 9th of 50 higher than 42 of 50 other Acute Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of XP20B Following Bunionectomy Surgery
COMPLETED · Phase 3
-
Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department
COMPLETED · Phase 3
-
Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion
COMPLETED · Phase 3
-
Erector Spinae Block Versus Surgeon Infiltration in VATS Procedures
COMPLETED · Phase 3
-
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
COMPLETED · Phase 3
-
Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia